Prelude Therapeutics Incorporated
PRLD
$1.00
$0.117313.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -16.50% | -11.86% | 11.16% | 3.00% | -4.77% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.77% | 1.21% | 11.95% | 14.71% | 17.96% |
| Operating Income | -0.77% | 9.49% | -2.97% | -14.71% | -17.96% |
| Income Before Tax | -2.08% | 13.13% | -5.43% | -14.16% | -13.40% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.08% | 13.13% | -5.43% | -14.16% | -13.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.08% | 13.13% | -5.43% | -14.16% | -13.40% |
| EBIT | -0.77% | 9.49% | -2.97% | -14.71% | -17.96% |
| EBITDA | -0.75% | 10.00% | -2.61% | -14.31% | -17.62% |
| EPS Basic | -1.73% | 20.32% | 5.99% | 15.27% | 28.52% |
| Normalized Basic EPS | -1.73% | 20.30% | 5.98% | 15.26% | 28.52% |
| EPS Diluted | -0.52% | 20.32% | 4.97% | 15.27% | 27.66% |
| Normalized Diluted EPS | -1.73% | 20.30% | 5.98% | 15.26% | 28.52% |
| Average Basic Shares Outstanding | 0.33% | 9.02% | 12.15% | 34.71% | 58.65% |
| Average Diluted Shares Outstanding | 0.33% | 9.02% | 12.15% | 34.71% | 58.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |